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ABSTRACT: The eﬀect of a newly developed
osmium(VI) nitrido complex, 1, on breast cancer stem
cells (CSCs) is reported. The complex displays selective
toxicity for HMLER breast cancer cells enriched with
CD44-positive, CSC-like cells over the same cells having
reduced CSC character. Remarkably, 1 also reduces the
proportion of CSCs within a heterogeneous breast cancer
cell population and irreversibly inhibits the formation of
free-ﬂoating mammospheres to an extent similar to that of
salinomycin, a natural product that targets CSCs. Detailed
mechanistic studies reveal that in breast cancer cells 1
induces DNA damage and endoplasmic reticulum stress,
the latter being responsible for the CSC selectivity. The
anti-CSC properties of 1 provide a strong impetus for the
development of new metal-based compounds to target
CSCs and to treat chemotherapy-resistant and relapsed
tumors.
Cancer relapse is strongly linked to the existence of cancerstem cells (CSCs), a small sub-population of tumor cells
that have the ability to self-renew, diﬀerentiate, and form
secondary or tertiary tumors.1 Conventional chemotherapy and
radiotherapy are ineﬀective against CSCs.2 Although current
therapies eﬀectively reduce tumor mass by destroying the bulk of
cancer cells, they cannot remove CSCs, which persist and
generate new tumors, often of a far more aggressive nature. To
improve clinical outcomes, treatments must have the ability to
kill the entirety of cancer cells, including CSCs. Compounds
capable of selectively killing CSCs and disrupting the micro-
environments supporting these cells are currently the subject of
intense research.3 Several potential CSC therapeutic targets have
been identiﬁed, such as cell surface markers4 and various
deregulated signaling pathways,5 but there is still no clinically
approved drug that speciﬁcally targets CSCs. A recent high-
throughput screen of ∼16,000 compounds, including commer-
cial libraries and collections of natural extracts, found only four
memberssalinomycin, abamectin, etoposide, and nigericin
to exhibit prominent CSC speciﬁcity.6 Thus, there is an urgent
need to discover new, selective compounds to add to this limited
arsenal of anti-CSC agents.
The quest for new CSC-targeting compounds has been
severely hampered by the inability to obtain and sustain CSC-
rich cell cultures.7 A recent study has shown, however, that
enriched populations of CSCs can be achieved by modifying
HMLER breast cancer cells through short hairpin RNA
(shRNA)-mediated inhibition of the CDH1 gene, which encodes
E-cadherin.8 Another study by the same group demonstrated that
CSC-enriched cultures could be generated by treating HMLER
cells with non-CSC-speciﬁc compounds, such as paclitaxel and
staurosporine.6 The latter approach relies on the ability of the
non-CSC-speciﬁc agents to kill bulk cancer cells, leaving stem-
like cells untouched. Here we sought to use these tools to
investigate the CSC-targeting ability of metal-based compounds,
including the newly developed osmium(VI) nitrido series, 1−3
(Figure 1). We recently reported their synthesis and anti-
proliferative properties.9 Encouragingly, 1−3 display selective
toxicity for cancer cells over healthy cells and no cross-resistance
with cisplatin, a clinically administered anticancer drug. In the
current study we examine the anti-CSC activity of 1−3 as well as
some well-established Pt(II)- and Pt(IV)-based antineoplastic
agents, also illustrated in Figure 1. The Os and Pt compounds
were prepared using previously reported methods.9,10 Prior to
carrying out cellular studies, the stability of 1, taken as a
representative member of the osmium(VI) nitrido series, in
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Figure 1. Chemical structures of the platinum(II and IV) and the
osmium(VI) nitrido complexes (1−3) under investigation.
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MEGM cell culture media was established by UV−vis spectros-
copy (Figure S1).
Experimentally transformed HMLER breast cancer cells11
were used to assess the CSC speciﬁcity of the metal complexes.
Under standard cell culture conditions, HMLER cells contain an
inherent CSC population of 5−8%. HMLER CSCs overexpress
CD44,4a a cell surface glycoprotein involved in cell signaling,
adhesion, and migration,12 and thus are deﬁned by a CD44high
marker proﬁle. Following reported protocols, CSC-enriched
HMLER cells were generated by paclitaxel treatment (10 nM for
4 days; Figure S2).6 This strategy enabled access to CSC-
enriched (>30%), CD44high HMLER cells (hereafter referred to
as HMLERtax cells).
The anti-proliferative properties of 1−3 against HMLER and
HMLERtax cells were assessed using the MTT assay. Identical
studies were also performed with compounds known to have
CSC-selective potency, such as salinomycin and abamectin.
FDA-approved Pt(II) anticancer drugs cisplatin, carboplatin, and
oxaliplatin,13 and Pt(IV) pro-drugs such as satraplatin14 and the
recently developed fatty-acid mimics Pt(IV)-C2 and Pt(IV)-
C16,10d were also investigated. The IC50 values (concentration
required to induce 50% inhibition) were derived from dose−
response curves (Figures 2A and S3−S12) and are summarized
in Table 1. Osmium complexes 1−3 displayed micromolar
toxicity toward both cell lines. Moreover, the 1,10-phen-
anthroline-bearing complex 1 exhibited selective toxicity for
HMLERtax cells over HMLER cells (2.3-fold). Salinomycin and
abamectin also killed HMLERtax cells preferentially over
HMLER cells (8.3- and 2.1-fold, respectively). None of the Pt-
based agents showed CSC selectivity. In fact, oxaliplatin,
satraplatin, and Pt(IV)-C16 exhibited 2−4.5-fold greater toxicity
for HMLER cells over HMLERtax cells (Figures S9, S10, and
S12). This result is consistent with the tendency of Pt
compounds to induce CSC enrichment rather than CSC
depletion (vide infra). Overall, the anti-proliferative data suggest
that 1 can selectively reduce the viability of CSC-enriched
HMLERtax cells over CSC-depleted HMLER cells, in the same
order of magnitude as salinomycin and abamectin, two of the
most selective CSC-targeting compounds identiﬁed to date.
Although salinomycin displays better selectivity for CSCs than 1,
1 exhibits a larger toxicity diﬀerential (the concentration
diﬀerence between the IC50 values for HMLER and HMLER
tax
cells). These properties are highly desirable for selecting CSC
drug candidates in preclinical studies.
To determine the eﬀect of the metal complexes on the
heterogeneity of breast cancer cells, ﬂow cytometric studies were
carried out. Upon treatment of HMLERtax cells with 1 (5−20 μM
for 4 days), a dose-dependent decrease in the proportion of
CD44high cells was observed, indicative of CSC-speciﬁc toxicity
(Figure 2B). A slight decrease in the CD44high population was
also observed upon incubation of HMLER cells with increasing
concentrations of 1 (5−40 μM for 4 days; Figure S13). Taken
together, the results demonstrate that 1 can selectively kill
CD44high CSC-like cells over bulk cancer cells. HMLERtax cells
treated with clinically approved Pt(II) anticancer drugs13
cisplatin (1.5 μM for 4 days), carboplatin (15 μM for 4 days),
and oxaliplatin (15 μM for 4 days) displayed little change in the
fraction of cells with CD44high character compared to the
untreated control (Figure S14). Moreover, upon treatment of
HMLER cells with the Pt drugs under the same conditions
described above, a marked increase in the relative CD44high
population was detected (3.2−5.4-fold), consistent with CSC
enrichment (Figure S15). These ﬁndings highlight the partiality
of conventional Pt(II)-based anticancer drugs to kill bulk cancer
cells over CSCs. In the same way as the Pt(II) compounds,
satraplatin treatment (1.5 μM for 4 days) did not alter the CSC
proportion in HMLERtax cells and propagated CSC enrichment
in HMLER cells (Figures S14 and S15), consistent with non-
CSC speciﬁcity.
Owing to their unlimited self-renewal ability, breast CSCs have
the tendency to form de novo tumor-like structures called
mammospheres in non-adherent, serum-free cell cultures.15 The
tumor sphere formation assay was used to assess the ability of 1,
salinomycin, paclitaxel, cisplatin, carboplatin, oxaliplatin, and
satraplatin (at their respective IC30 values) to inhibit mammo-
sphere formation from HMLER single-cell suspensions. To
obtain 3D images of the mammospheres and determine the
proportion of CD44-positive cells within a given mammosphere,
the cells were stained with Hoechst 33258 dye (7.5 μM for 30
min) and allophycocyanin (APC)-labeled anti-CD44 antibody
(15 μL, 1:133 dilution for 45 min), respectively, and imaged
using a ﬂuorescence microscope (Figure S16). The tumorsphere
formation assay showed that treatment with 1 induced a 38%
decrease in the number of mammospheres formed relative to the
untreated control, providing strong evidence for the inhibition of
CSC self-renewal (Figure 3). The microscopy studies revealed
that the size of the spheroids decreased by up to 2.4-fold in the
presence of 1 (Figure 3). Furthermore, upon incubation with 1,
Figure 2. (A) Average dose−response curves for the treatment of
HMLER and HMLERtax cells with 1 (n = 30 for each point). (B)
Representative histograms displaying the red ﬂuorescence emitted by
anti-CD44 APC antibody-stained HMLER cells (red), HMLERtax cells
(blue), and HMLERtax cells treated with 1 (5 μM, orange; 10 μM, light
green; 20 μM, dark green) for 4 days followed by 4 days recovery in
compound-free MEGM media.
Table 1. IC50 Values of Tested Compounds against HMLER
and HMLERtax Cells
compound
HMLER
IC50 (μM)
HMLERtax
IC50 (μM)
selectivity for
HMLERtax a
1 11.20 ± 0.48 4.91 ± 0.86 2.31
2 14.58 ± 0.20 16.06 ± 4.12 0.91
3 82.80 ± 18.43 53.99 ± 2.45 1.53
salinomycin 0.49 ± 0.26 0.058 ± 0.01 8.45
abamectin 1.45 ± 0.18 0.64 ± 0.06 2.26
cisplatin 1.95 ± 0.40 2.06 ± 0.67 0.95
carboplatin 17.84 ± 0.58 18.19 ± 0.80 0.98
oxaliplatin 15.04 ± 0.41 26.95 ± 4.42 0.55
satraplatin 1.22 ± 0.06 2.87 ± 0.23 0.43
Pt(IV)-C2 39.09 ± 9.82 40.64 ± 9.91 0.96
Pt(IV)-C16 0.0254 ± 0.0016 0.1131 ± 0.0197 0.22
aSelectivity = IC50 for HMLER/IC50 for HMLER
tax. The values
reported are an average of ﬁve independent determinations.
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the proportion of CD44-positive cells within a given mammo-
sphere was markedly diminished, indicative of CSC-speciﬁc
toxicity (Figure S16). Collectively, these data show that 1 inhibits
the clonogenic growth of HMLER mammospheres by
eliminating CD44-positive, CSC-like cells. As expected, a
reduction in both mammosphere number and size (up to 1.4-
fold) was observed for salinomycin treatment (positive control,
Figure 3). In contrast, paclitaxel, carboplatin, and satraplatin
treatment led to an increase in the number of mammospheres
formed (10−40%), suggestive of CSC enrichment (Figure 3).
This result was corroborated by a 2−4-fold increase in the
number of CD44-positive cells within the mammospheres
(Figure S16). The number of mammospheres formed was
marginally reduced by cisplatin and oxaliplatin treatment, but the
size of the spheroids remained largely unaltered (Figure 3).
To determine whether 1 could induce a durable mammo-
sphere inhibitory response, 1-treated primary mammospheres
were dissociated into single-cell suspensions, and their
propensity to form secondary mammospheres was assessed
(Figure S17). Control studies were also conducted with
salinomycin- and paclitaxel-treated primary mammospheres.
The secondary mammospheres formed from cells isolated from
1-treated primary mammospheres were 5-fold fewer than those
from the untreated control. This result shows that 1 inhibits the
self-renewal of HMLER mammospheres and that this eﬀect is
maintained upon serial passage. Cells extracted from salino-
mycin-treated primary mammospheres displayed non-clono-
genic properties, similar to those observed for 1-treated cells.
Single-cell suspensions of paclitaxel-treated primary mammo-
spheres, on the other hand, produced slightly more secondary
mammospheres compared to the untreated control.
To account for the CSC-speciﬁcity and mammosphere
potency observed for 1, detailed mechanistic studies were
conducted. The Os complex 1 was previously characterized via
an RNAi signature approach16 capable of discerning drug
mechanism of action.9 Although 1 did not resemble any category
of drug mechanism present in the reference set, the pleiotropic
mechanism of 1-induced cell death appeared to involve DNA
damage. Given the nature of other Os compounds in eliciting
endoplasmic reticulum (ER) stress,9 we added known ER stress
inducers tunicamycin and thapsigargin to the RNAi signature
training set (Figure 4A). Upon re-analysis of the RNAi
signatures, we found that 1 still did not belonging to any training
set category. Thus, we next examined the signatures of 1, ER
stress inducers tunicamycin and thapsigargin, and representative
DNA-cross-linkers cisplatin, carboplatin, and chlorambucil via
principal components analysis (PCA). PCA represents the
variance of a multi-dimensional data set in successive principal
components where each component represents a larger portion
of the data set variance than the next. By plotting the
aforementioned compounds via PCA, we found that 1 lies
roughly equidistant between the canonical ER stress inducers
and DNA-cross-linkers (Figure 4B). This result indicated that 1
can induce cell death via both mechanisms.
Immunoblotting studies were conducted to monitor changes
in expression of biomarkers related to the DNA damage and ER
stress pathways. HMLER cells incubated with 1 (5−20 μM for 72
h) displayed a marked increase in the expression of the
phosphorylated forms of H2AX and CHK2, indicative of DNA
damage (Figure S18).17 DNA damage is usually accompanied by
p53 accumulation and upregulation of downstream eﬀectors
related to cell cycle arrest, DNA repair, and apoptosis.18 Owing
to the inactivation of p53 in HMLER cells, however, the
expression of p21, a p53 eﬀector, remained unchanged upon
treatment with 1(5−20 μM for 72 h; Figure S18). The inability of
p53 to coordinate cellular response following DNA damage in
HMLER cells suggests that 1-induced DNA damagemay not be a
major determinant of cell death. HMLER cells dosed with 1 (5−
20 μM for 72 h) exhibited an increase in the expression of
proteins related to the unfolded protein response, such as
phosphorylated eukaryotic initiation factor 2α (eIF2α) and
C/EBP homologous protein, suggestive of ER stress (Figure
S18).19 Immunoﬂuorescence studies showed that, upon
incubation of HMLER cells with 1 (25 μM for 24 h), the
expression of the phosphorylated RNA-dependent protein
kinase-like endoplasmic reticulum kinase (phospho-PERK)
increased. This ﬁnding provided further evidence of ER stress
Figure 3.Quantiﬁcation of mammosphere formation withHMLER cells
untreated and treated with the investigated compounds at their
respective IC30 values for 5 days. Representative bright-ﬁeld images
(×4) of the mammospheres formed under each condition are presented
to scale. Scale bar = 0.3 mm. Student t test, p < 0.05 or p < 0.01. Error
bars represent standard deviations.
Figure 4. (A) RNAi signatures derived from the treatment of Eμ-
Mycp19arf−/− lymphoma cells with 1, ER stress inducers tunicamycin and
thapsigargin, and DNA-cross-linking agents cisplatin, carboplatin, and
chlorambucil at the LD80−90 concentration for each compound. (B)
Principal components analysis plot of the RNAi signatures.
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(Figure S19).19 A similar result was also observed for HMLER
cells treated with thapsigargin (0.25 μM for 24 h; Figure S19).
HMLER cells treated with 1 (5−20 μM for 72 h) displayed an
increase in the expression of cleaved caspase 3 and 7, and poly-
ADP ribose polymerase (Figure S18). Thus, the mode of 1-
induced cell death is most likely to be caspase-dependent
apoptosis. Taken together, the immunoblotting and immuno-
ﬂuorescence data reveal that in breast cancer cells 1 initiates both
DNA damage and ER stress, culminating in apoptotic cell death.
A recent study identiﬁed the vulnerability of HMLER CSC-
like cells to agents that can induce ER stress through the PERK-
eIF2α axis.20 In light of this report and our mechanistic data, we
propose that the CSC speciﬁcity observed for 1 could be
attributed to the ability of the complex to induce ER stress. To
investigate this hypothesis, the toxicity of 1 against HMLER and
HMLERtax cells in the absence and presence of a known ER stress
inhibitor, salubrinal,21 was determined. Co-administration of
HMLER and HMLERtax cells with 1 and salubrinal (10 μM)
signiﬁcantly reduced the cytotoxicity of 1 in CSC-enriched
HMLERtax cells (t test, p < 0.05) but not in CSC-depleted
HMLER cells (t test, p = 0.30; Figure S20). Thus, 1 induces ER
stress-mediated cell death in CSCs more readily than in non-
CSCs. Overall, our mechanistic studies show that the CSC
speciﬁcity observed for 1 likely results from the ability of 1 to
induce ER stress via the PERK-eIF2α pathway and the sensitivity
of HMLER CSCs to ER stress inducers.
In summary, we present the anti-CSC properties of 1. To our
knowledge, 1 is the ﬁrst osmium-based compound to exhibit
selective toxicity for breast CSC-enriched cell populations.
Encouragingly, the CSC-speciﬁc potency of 1 challenges some of
the most CSC-selective compounds identiﬁed to date. Addition-
ally, 1 inhibits the formation of mammospheres by speciﬁcally
targeting CD44-positive, CSC-like cells. Given our ﬁndings and
the urgent medical need for CSC-speciﬁc chemotherapies to
overcome cancer relapse and metastases formation in the clinic,
the anti-CSC properties of 1 are pre-clinically very appealing.
Overall, this study highlights the great, largely unexplored
potential of metal-based complexes for CSC-directed chemo-
therapy and provides hints about the mechanism and targets of
systemic Os toxicity.
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